GERON CORP. news, videos and press releases - Page 3
For more news please use our advanced search feature.
GERON CORP. - More news...
GERON CORP. - More news...
- Investor Alert: Robbins LLP Informs Investors of the Geron Corporation Class Action Lawsuit
- Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights
- Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
- Geron Corporation Announces Departure of Chief Executive Officer
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
- Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Geron to Participate at Upcoming Investor Conferences in March 2025
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
- Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
- Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
- Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
- Geron to Participate in the Stifel 2024 Healthcare Conference
- Thinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?
- Thinking about buying stock in Minim, GameSquare, Laser Photonics, Geron, or Mind Medicine?
- Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
- Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
- Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
- Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
